Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × atezolizumab × Clear all

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 19 Breast Neoplasms 10 Triple Negative Breast Neoplasms 9 Carcinoma, Transitional Cell 8 Small Cell Lung Carcinoma 6 Colorectal Neoplasms 6 Neoplasm Metastasis 5 Carcinoma, Hepatocellular 5 Recurrence 4 Neoplasms 4 Melanoma 4 Lung Neoplasms 4 Carcinoma, Renal Cell 4 Urinary Bladder Neoplasms 3 Solid Tumor 2 Lymphoma, B-Cell 2 Lymphoma 2 Liver Neoplasms 2 Leukemia, Myeloid, Acute 2 Kidney Neoplasms 2 Head and Neck Neoplasms 2 Brain Neoplasms 2 Advanced Solid Tumor 2 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Solid Tumour 1 Solid Tumors 1

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡